The U.S. nucleic acid synthesis screening policy sets new supplier, customer and equipment controls for pharma and biotech research governance and procurement.
Screening policy issued by the White House on 5 November 2026 for nucleic acid synthesis introduces a new level of accountability for federally funded life sciences research.
The policy clearly moves U.S. biosecurity oversight towards independently verified supplier screening, customer identity checks, and tighter controls over laboratory DNA synthesis equipment.
For pharma and biotechnology companies, the policy has significant implications for procurement, research governance, and AI-enabled biological innovation.
Image
Why Has the U.S. Introduced a New Nucleic Acid Screening Policy?
Nucleic acid synthesis is essential to modern pharmaceutical research. Companies use synthetic DNA and RNA in drug discovery, vaccine development, genetic engineering, cell and gene therapies, and biological manufacturing.
However, the same technologies can support harmful biological research.
The concern is that malicious actors could order synthetic genetic material to develop or modify biological agents with dangerous properties.
The new policy follows Executive Order 14292, Improving the Safety and Security of Biological Research, issued on 5 May 2025.
That order directed the U.S. Government to replace its existing 2024 Framework for Nucleic Acid Synthesis Screening with stronger, independently verifiable safeguards.
The November 2026 policy establishes that exact framework.
Its introduction also reflects a changing technological environment. AI-powered biological design tools can generate sequences that do not necessarily resemble known hazardous biological sequences closely enough to trigger conventional screening systems.
A recent National Institute of Standards and Technology (NIST) publication examined this problem, highlighting the limitations of relying exclusively on sequence similarity to identify biological risks.
The regulatory response is therefore moving towards a more adaptive screening model.
The central change is a shift from relying on supplier declarations to requiring independently verified screening infrastructure.
“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."
Image
What Does the New Nucleic Acid Screening Policy Require?
The policy applies to recipients and subrecipients of U.S. federal life sciences funding that purchase synthetic nucleic acids or benchtop nucleic acid synthesis equipment.
It establishes a procurement requirement: Covered organisations must obtain these materials and equipment exclusively from suppliers that meet the new federal adherence standards.
The policy targets synthetic nucleic acid orders of 50 or more nucleotides, consistent with the baseline established in the 2023 HHS Screening Framework Guidance.
It introduces several important requirements.
1. Independent verification of screening systems
The National Institute of Standards and Technology (NIST) will develop the technical standards and testing protocols used to assess screening tools.
Suppliers must submit every in-scope order to a NIST-verified screening service before fulfilment.
These screening systems must assess:
Potential sequences of concern (SOCs).
Customer legitimacy where an order contains a sequence of concern.
Whether an order presents unresolved security concerns.
NIST will also maintain a list of verified screening providers.
This introduces an independent verification layer. Suppliers can no longer rely solely on their own declarations that their screening systems meet acceptable standards.
First, suppliers must verify customers when establishing a commercial relationship and periodically repeat those checks.
Second, the verified screening service must independently assess customer legitimacy at the individual order level when a sequence of concern is identified.
These checks consider customer identity, institutional affiliation, authorisation, and whether the proposed use is consistent with the organisation's activities.
This creates a stronger connection between biological material procurement and the identity and legitimacy of the organisation requesting it.
Image
3. Greater supplier accountability
Suppliers retain responsibility for deciding whether to fulfil or reject an order.
A screening determination does not automatically authorise a transaction. Suppliers must exercise independent judgement, document their decisions, and report unresolved concerns to the appropriate federal authorities.
They must also retain screening records and relevant customer interactions for at least eight years.
This includes records associated with flagged orders, screening outcomes, customer verification, and the actions taken following concerns.
4. Controls over benchtop synthesis equipment
One of the policy’s more significant developments concerns laboratory-based DNA synthesis.
Previously, screening requirements focused heavily on commercial synthesis providers. However, benchtop equipment allows researchers to synthesise nucleic acids within individual laboratories.
The new policy addresses this gap through equipment-level authorisation.
NIST will establish two operating categories:
Tier 1: Networked authorisation. Equipment must receive valid, current approval from a verified screening service before starting synthesis. This is the default operating model.
Tier 2: Bounded offline operation. Equipment without network connectivity may operate under limited conditions, but only where NIST has verified the relevant technical safeguards.
Equipment must also maintain tamper-resistant records of authorisations, declined requests, and synthesis activity.
These requirements have direct implications for laboratory equipment manufacturers, distributors, and research institutions.
What Are the Implementation Deadlines for Research Companies?
The policy takes effect immediately, although its requirements will be introduced through a staged implementation programme.
NIST, the U.S. Health and Human Services, and other federal agencies will lead the process.
The published implementation schedule establishes the following milestones:
Implementation milestone
Deadline
Policy publication
Day 0
NIST publishes screening and equipment standards
Day 90
NIST begins verifying screening providers
Day 100
HHS publishes the initial adherent supplier list
Day 160
Federal funding recipients procure synthetic nucleic acids exclusively through adherent suppliers
Day 250
Federal funding recipients procure benchtop equipment exclusively through adherent suppliers
Day 340
Using the 5 November 2026 publication date, the principal deadlines fall in February, April, July, and October 2027.
The 2024 framework remains relevant during the transition. It will be superseded when the new policy reaches full implementation.
Importantly, the policy also introduces financial consequences for non-compliance.
Federal funding agencies must incorporate the requirements into their funding agreements. Violations may result in immediate withdrawal of ongoing federal funding and ineligibility for federal funding for up to five years, alongside other applicable legal penalties.
For pharmaceutical companies working with U.S.-funded academic institutions, research partners, or suppliers, these provisions warrant early attention.
AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Image
Why Does the Policy Matter for Pharmaceutical and Biotechnology Companies?
The policy has implications beyond U.S. government-funded laboratories.
Pharmaceutical companies operate through interconnected networks of contract research organisations, universities, biotechnology suppliers, synthesis providers, and international research partners.
Many of these organisations depend on synthetic nucleic acids to support legitimate therapeutic development.
The new requirements could therefore influence supplier qualification, procurement contracts, research collaboration agreements, and equipment purchasing decisions.
Image
Three areas deserve particular attention.
Supplier qualification and procurement
Pharmaceutical procurement teams should establish whether their existing suppliers intend to pursue adherence under the new framework.
Organisations should also review contractual arrangements, alternative suppliers, and the potential impact of equipment replacement.
Research governance and collaboration
Companies working with federally funded institutions will need to understand how procurement restrictions affect material transfers, shared research infrastructure, and cross-border collaborations.
The policy also introduces restrictions concerning certain foreign affiliations and entities of concern.
AI and biological security
The policy connects directly with the growing challenge of AI-enabled biological design.
As AI systems become more capable of generating novel biological sequences, screening mechanisms must evolve beyond conventional reference-list comparisons.
Together, these developments illustrate how governments are beginning to treat biological security as an integral part of technological and pharmaceutical governance.
There are also practical questions that remain unresolved.
NIST still needs to publish the detailed technical standards, performance criteria, verification procedures, and data-handling requirements.
The effectiveness of the framework will depend heavily on how these requirements work in practice.
The industry must also consider how independent screening can protect commercially sensitive research information. The policy directs NIST to establish limits on the retention and use of customer, order, and sequence data by screening providers.
These safeguards will be important for maintaining industry confidence.
What Comes Next for Biosecurity Regulation?
The U.S. nucleic acid synthesis screening policy represents a significant development in the governance of synthetic biology.
The policy establishes a clearer accountability structure for suppliers, introduces independent screening verification, and extends controls to laboratory synthesis equipment.
However, its immediate legal reach remains tied to federally funded procurement. It does not automatically establish a universal screening mandate for every privately funded pharmaceutical research programme or every international supplier.
This will be difficult to manage for many organisations operating across multiple jurisdictions.
The next stage will depend on NIST’s technical standards, the supplier verification process, and how federal agencies incorporate the requirements into funding agreements.
If you’re a lab using nucleic acid synthesis, waiting until the final procurement deadlines would create unnecessary operational risk. Supplier assessments, contractual reviews, equipment inventories, and research governance evaluations should begin well before 2027 implementation milestones.
At Pharmatica, we examine the Regulatory frameworks, Research developments, and Technologies shaping pharmaceutical innovation. Our Insights help industry leaders understand how emerging policies affect research, commercial operations, and long-term strategic decisions.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What is the U.S. National Policy for Nucleic Acid Synthesis Screening?
The National Policy for Nucleic Acid Synthesis Screening is a U.S. Government policy issued on 5 November 2026. It establishes mandatory supplier verification, sequence screening, and customer identity requirements for federally funded life sciences procurement of synthetic nucleic acids and benchtop synthesis equipment.
Who must comply with the 2026 nucleic acid screening policy?
Recipients and subrecipients of U.S. federal life sciences funding must procure covered synthetic nucleic acids and benchtop synthesis equipment exclusively from adherent suppliers under the implementation schedule.
What is a verified nucleic acid screening provider?
A verified screening provider is a service or tool assessed and approved by NIST against federal technical standards. It evaluates sequences of concern, relevant customer legitimacy, and flagged orders before suppliers fulfill eligible requests.
Does the new U.S. biosecurity policy cover benchtop DNA synthesis equipment?
Yes. The policy requires benchtop synthesis equipment to use verified authorisation before initiating synthesis. Limited offline operation may be permitted under technical conditions established and verified by NIST.
What happens if an organisation violates the nucleic acid synthesis screening policy?
Non-compliance may result in immediate withdrawal of ongoing federal funding and ineligibility for federal funding for up to five years. Other penalties may also apply under existing federal laws and regulations.
Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.
Did you enjoy the content?
0
Why not support
Nicole Dale
by giving this content a like
Decentralised Clinical Trials: Balance Innovation and Integrity
Decentralised clinical trials expand access and reduce patient burden. Learn how sponsors balance innovation in DCT design, data integrity, and regulatory compliance.
How Cortical Implants Are Opening a New Era of Vision Restoration
By directly stimulating the visual cortex instead of relying on the retina or optic nerve, ReVision's FDA Breakthrough Device-designated implant could make vision restoration possible for millions of patients who have no existing treatment options.
Designing Decentralised Clinical Trials for Patient Diversity
Data shows that most DCT approaches significantly improve patient diversity. This analysis examines what the evidence means for clinical trial design strategy.
Decentralised clinical trials promise to transform drug development and pharma strategy. The evidence tells a complex story. Here is what’s working and what still needs to be fixed.
Ethical obligations in decentralised clinical trials extend beyond consent and privacy. Sponsors must protect safety, scientific validity, equity, and oversight.
Comments (0)